数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael F. Mahoney CEO, Chairman of the Board 59 1694.20万美元 376.89 2024-03-01
Yoshiaki Fujimori Independent Director 73 32.00万美元 3.67 2024-03-01
Jessica L. Mega Independent Director 49 未披露 0.33 2024-03-01
Susan E. Morano Independent Director -- 未披露 0.42 2024-03-01
Ellen M. Zane Independent Director 72 32.00万美元 4.56 2024-03-01
Edward J. Ludwig Independent Director 72 36.00万美元 8.86 2024-03-01
John E. Sununu Independent Director 59 34.00万美元 13.15 2024-03-01
Charles J. Dockendorff Independent Director 69 34.50万美元 6.39 2024-03-01
David S. Wichmann Independent Director 61 32.00万美元 4.30 2024-03-01
David J. Roux Independent Director 67 34.00万美元 7.36 2024-03-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael F. Mahoney CEO, Chairman of the Board 59 1694.20万美元 376.89 2024-03-01
John B. Sorenson Executive Vice President,Global Operations 56 未披露 未持股 2024-03-01
Eric Thepaut Executive Vice President and President, Europe,Middle East and Africa 62 未披露 未持股 2024-03-01
Arthur C. Butcher Executive Vice President and Group President,MedSurg and Asia Pacific 53 417.34万美元 23.43 2024-03-01
Vance R. Brown Senior Vice President, General Counsel, Corporate Secretary 54 未披露 未持股 2024-03-01
Jonathan Monson -- Senior Vice President, Investor Relations -- 未披露 未持股 2024-03-01
Emily Woodworth Senior Vice President, Global Controller and Chief Accounting Officer 46 未披露 未持股 2024-03-01
Joseph M. Fitzgerald Executive Vice President and Group President,Cardiology 60 476.46万美元 98.72 2024-03-01
Wendy Carruthers Executive Vice President,Human Resources 55 未披露 未持股 2024-03-01
Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions 58 356.22万美元 33.37 2024-03-01
Daniel J. Brennan Executive Vice President and Chief Financial Officer 58 525.22万美元 65.30 2024-03-01

董事简历

中英对照 |  中文 |  英文
Michael F. Mahoney

Michael F. Mahoney,自2012年11月起担任公司总裁、首席执行官兼董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。


Michael F. Mahoney,has been the President of Boston Scientific Corporation ("Boston Scientific"; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. Mr. Mahoney has a bachelor's degree in Finance from the University of Iowa and an M.B.A. from Wake Forest University. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. (NYSE: BAX), a multinational health care company. He is currently a member of the Board of Directors of the Boys and Girls Club of Boston, a member of the American Heart Association CEO Roundtable, and is Chair of the Board of Governors of the Boston College Chief Executives Club.
Michael F. Mahoney,自2012年11月起担任公司总裁、首席执行官兼董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney,has been the President of Boston Scientific Corporation ("Boston Scientific"; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. Mr. Mahoney has a bachelor's degree in Finance from the University of Iowa and an M.B.A. from Wake Forest University. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. (NYSE: BAX), a multinational health care company. He is currently a member of the Board of Directors of the Boys and Girls Club of Boston, a member of the American Heart Association CEO Roundtable, and is Chair of the Board of Governors of the Boston College Chief Executives Club.
Yoshiaki Fujimori

Yoshiaki Fujimori,他一直担任Boston Scientific公司的董事(2016年7月以来)。他目前担任the LIXIL Group Corporation的顾问(2016年6月以来),也曾担任the LIXIL Group Corporation的总裁兼首席执行官(2011年8月至2016年6月)。加入LIXIL之前,他曾担任GE Japan公司的董事长、总裁和首席执行官(从2008年1月到2011年6月)。他曾任职GE25年(始于1986年10月),担任多种职务,包括许多亚洲和全球的业务部门的高级副总裁兼首席执行官,其中包括医疗系统、塑料和资本。他也曾担任the GE Corporate Executive Council的成员(从2001年到2010年)。他一直担任Tokyo Electric Power Company的外部董事(2012年6月以来)、Takeda Pharmaceutical Company Limited的外部董事(2016年6月以来),此前曾担任the Japan Construction Material & Housing Equipment Industries Federation的董事。他持有the Tokyo University of Science的石油工程学士学位、Carnegie Mellon Graduate School of Business的工商管理硕士学位,在那里他曾担任监事会的终身成员。


Yoshiaki Fujimori,served as External Director who is not a member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2022 and was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2022. Mr. Fujimori currently also serves as Senior Executive Advisor of CVC Asia Pacific (Japan) Kabushiki Kaisha, External Director and Chairman of Oracle Corporation Japan, External Director of Riraku K.K. and Trygroup Inc. He previously served as External Director of Tokyo Electric Power Company, Incorporated (currently Tokyo Electric Power Company Holdings, Incorporated), External Director of Toshiba Corporation, External Director of Shiseido Company, Limited and in a number of senior leadership positions within the LIXIL Group, including Representative Director, Chairman and CEO of LIXIL Corporation. Mr. Fujimori has also served in a number of senior positions in the General Electric Group, including Chairman of GE Japan Corporation and Chairman, President and CEO of General Electric Japan Ltd.
Yoshiaki Fujimori,他一直担任Boston Scientific公司的董事(2016年7月以来)。他目前担任the LIXIL Group Corporation的顾问(2016年6月以来),也曾担任the LIXIL Group Corporation的总裁兼首席执行官(2011年8月至2016年6月)。加入LIXIL之前,他曾担任GE Japan公司的董事长、总裁和首席执行官(从2008年1月到2011年6月)。他曾任职GE25年(始于1986年10月),担任多种职务,包括许多亚洲和全球的业务部门的高级副总裁兼首席执行官,其中包括医疗系统、塑料和资本。他也曾担任the GE Corporate Executive Council的成员(从2001年到2010年)。他一直担任Tokyo Electric Power Company的外部董事(2012年6月以来)、Takeda Pharmaceutical Company Limited的外部董事(2016年6月以来),此前曾担任the Japan Construction Material & Housing Equipment Industries Federation的董事。他持有the Tokyo University of Science的石油工程学士学位、Carnegie Mellon Graduate School of Business的工商管理硕士学位,在那里他曾担任监事会的终身成员。
Yoshiaki Fujimori,served as External Director who is not a member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2022 and was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2022. Mr. Fujimori currently also serves as Senior Executive Advisor of CVC Asia Pacific (Japan) Kabushiki Kaisha, External Director and Chairman of Oracle Corporation Japan, External Director of Riraku K.K. and Trygroup Inc. He previously served as External Director of Tokyo Electric Power Company, Incorporated (currently Tokyo Electric Power Company Holdings, Incorporated), External Director of Toshiba Corporation, External Director of Shiseido Company, Limited and in a number of senior leadership positions within the LIXIL Group, including Representative Director, Chairman and CEO of LIXIL Corporation. Mr. Fujimori has also served in a number of senior positions in the General Electric Group, including Chairman of GE Japan Corporation and Chairman, President and CEO of General Electric Japan Ltd.
Jessica L. Mega

Jessica L. Mega自2015年3月起担任Verily Life Sciences LLC (Alphabet Inc.的子公司,专注于生命科学和医疗保健)的首席医疗和科学官。加入Verily之前,她曾担任Brigham & Women 's Hospital的心脏病专家和高级调查员(从2008年到2015年3月)。Mega博士也曾担任Harvard Medical School的教员和TIMI Study Group的高级研究员,在那里她帮助领导评估新型心血管疗法的国际试验,并指导遗传学项目。Mega博士负责监督Verily的临床和科学工作,专注于将技术创新和科学见解转化为改善患者预后的合作伙伴和项目。


Jessica L. Mega,co-founded and served as Chief Medical and Scientific Officer at Verily Life Sciences LLC, a subsidiary of Alphabet Inc. focused on life sciences and healthcare, from March 2015 to January 2023. Prior to joining Verily, she served as Cardiologist and Senior Investigator at Brigham & Women's Hospital from 2008 to March 2015. Dr. Mega has also served as a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, where she helped lead international trials evaluating novel cardiovascular therapies and directed the genetics program. At Verily, Dr. Mega oversaw Verily's clinical and science efforts, focusing on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. Dr. Mega's clinical background and experience re-imagining how clinical trial data is collected and analyzed offer valuable insights for Danaher, given Danaher Corporation strategic focus on life sciences and healthcare applications. Dr. Mega received her B.A. from Stanford University, her M.D. from Yale University School of Medicine, and her M.P.H. from Harvard School of Public Health.
Jessica L. Mega自2015年3月起担任Verily Life Sciences LLC (Alphabet Inc.的子公司,专注于生命科学和医疗保健)的首席医疗和科学官。加入Verily之前,她曾担任Brigham & Women 's Hospital的心脏病专家和高级调查员(从2008年到2015年3月)。Mega博士也曾担任Harvard Medical School的教员和TIMI Study Group的高级研究员,在那里她帮助领导评估新型心血管疗法的国际试验,并指导遗传学项目。Mega博士负责监督Verily的临床和科学工作,专注于将技术创新和科学见解转化为改善患者预后的合作伙伴和项目。
Jessica L. Mega,co-founded and served as Chief Medical and Scientific Officer at Verily Life Sciences LLC, a subsidiary of Alphabet Inc. focused on life sciences and healthcare, from March 2015 to January 2023. Prior to joining Verily, she served as Cardiologist and Senior Investigator at Brigham & Women's Hospital from 2008 to March 2015. Dr. Mega has also served as a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, where she helped lead international trials evaluating novel cardiovascular therapies and directed the genetics program. At Verily, Dr. Mega oversaw Verily's clinical and science efforts, focusing on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. Dr. Mega's clinical background and experience re-imagining how clinical trial data is collected and analyzed offer valuable insights for Danaher, given Danaher Corporation strategic focus on life sciences and healthcare applications. Dr. Mega received her B.A. from Stanford University, her M.D. from Yale University School of Medicine, and her M.P.H. from Harvard School of Public Health.
Susan E. Morano

Susan E. Morano,从2020年到2023年2月担任Johnson & Johnson MedTech业务发展和战略运营副总裁。在此之前,她从2012年开始担任Johnson & Johnson Medical Devices的业务发展副总裁,负责其医疗设备集团的许可、收购和剥离。在Johnson & Johnson任职期间,Morano女士还在六家运营公司担任多个职位,主要负责财务和业务发展职能,并担任MedTech领导团队的成员。她持有Villanova University的学士学位和Columbia Business School的工商管理硕士学位。


Susan E. Morano,held the role of vice president, Business Development and Strategic Operations, Johnson & Johnson MedTech from 2020 through February 2023. Prior to that, she served as vice president, Business Development, Johnson & Johnson Medical Devices, beginning in 2012, with responsibility for licensing, acquisitions and divestitures for its Medical Devices Group. During her time at Johnson & Johnson, Ms. Morano also held several positions within six operating companies, primarily in the finance and business development functions, and as a member of the MedTech Leadership Team. Ms. Morano received her B.S. from Villanova University and her M.B.A. from Columbia Business School.
Susan E. Morano,从2020年到2023年2月担任Johnson & Johnson MedTech业务发展和战略运营副总裁。在此之前,她从2012年开始担任Johnson & Johnson Medical Devices的业务发展副总裁,负责其医疗设备集团的许可、收购和剥离。在Johnson & Johnson任职期间,Morano女士还在六家运营公司担任多个职位,主要负责财务和业务发展职能,并担任MedTech领导团队的成员。她持有Villanova University的学士学位和Columbia Business School的工商管理硕士学位。
Susan E. Morano,held the role of vice president, Business Development and Strategic Operations, Johnson & Johnson MedTech from 2020 through February 2023. Prior to that, she served as vice president, Business Development, Johnson & Johnson Medical Devices, beginning in 2012, with responsibility for licensing, acquisitions and divestitures for its Medical Devices Group. During her time at Johnson & Johnson, Ms. Morano also held several positions within six operating companies, primarily in the finance and business development functions, and as a member of the MedTech Leadership Team. Ms. Morano received her B.S. from Villanova University and her M.B.A. from Columbia Business School.
Ellen M. Zane

Ellen M. Zane是塔夫茨医疗中心的名誉首席执行官,此前她曾担任该中心的总裁兼首席执行官。Zane女士还担任过Mass General Brigham的网络总裁,该网络以前是Partners Healthcare System,这是一个由哈佛附属麻省总医院和Brigham and Women's Hospital赞助的医生/医院网络。Zane还曾在马萨诸塞州昆西的昆西医院担任首席执行官。Zane女士目前担任Savista(一家总部位于格鲁吉亚的从事医疗保健收入周期管理的私营公司)、Fiduciary Trust Company(一家私营财富管理公司)和AgNovos Healthcare,LLC(一家私营医疗设备公司)的董事,该公司专注于骨骼健康。Zane此前曾担任Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey Holdings的董事。Zane女士拥有美国公司董事学院的专业董事高级证书。


Ellen M. Zane,joined Haemonetics Corporation Board in January 2018 and serves as the Chair of the Board, Chair of the Governance and Compliance Committee and a member of the Compensation Committee. Ms. Zane is CEO Emeritus of Tufts Medical Center, where she served as President and Chief Executive Officer from 2004 to 2011. Prior to 2004, Ms. Zane served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane has previously served as a director of Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane previously served on the Company's Board from 2012 to 2016. Ms. Zane was named to the NACD Directorship 100 for 2021, an annual award that recognizes the most influential boardroom leaders each year.
Ellen M. Zane是塔夫茨医疗中心的名誉首席执行官,此前她曾担任该中心的总裁兼首席执行官。Zane女士还担任过Mass General Brigham的网络总裁,该网络以前是Partners Healthcare System,这是一个由哈佛附属麻省总医院和Brigham and Women's Hospital赞助的医生/医院网络。Zane还曾在马萨诸塞州昆西的昆西医院担任首席执行官。Zane女士目前担任Savista(一家总部位于格鲁吉亚的从事医疗保健收入周期管理的私营公司)、Fiduciary Trust Company(一家私营财富管理公司)和AgNovos Healthcare,LLC(一家私营医疗设备公司)的董事,该公司专注于骨骼健康。Zane此前曾担任Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey Holdings的董事。Zane女士拥有美国公司董事学院的专业董事高级证书。
Ellen M. Zane,joined Haemonetics Corporation Board in January 2018 and serves as the Chair of the Board, Chair of the Governance and Compliance Committee and a member of the Compensation Committee. Ms. Zane is CEO Emeritus of Tufts Medical Center, where she served as President and Chief Executive Officer from 2004 to 2011. Prior to 2004, Ms. Zane served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane has previously served as a director of Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane previously served on the Company's Board from 2012 to 2016. Ms. Zane was named to the NACD Directorship 100 for 2021, an annual award that recognizes the most influential boardroom leaders each year.
Edward J. Ludwig

Edward J. Ludwig于2011年10月31日进入公司董事会。他于2012年7月在贝克顿公司、迪金森公司和BD公司担任董事长职务。他于1979年加入BD 公司,自2000年1月至2011年9月期间内他担任首席执行官、总裁、财务总监以及其他职务。再加入BD公司之前,他在永道会计师事务所(现在被称为普华永道律师事务所)担任高级审计师,在此期间内,他获得了注册会计师资格证。并且在基德公司担任财务与策略分析师。他在安泰保险公司董事会担任首席董事,并在财务委员会董事会担任主席。他也在波士顿科学公司董事会任职。他在哈肯萨克大学医学中心网络董事会担任副董事长,他是战略咨询委员会资金使用费部门的一员并在POCARED公司担任主管。他是更高职员领导中心董事会成员之一。他任职于哥伦比亚商学院监督委员会。他在美国先进医疗技术协会担任董事会主席,美国先进医疗技术协会是世界上最大的医疗技术协会。他在约翰霍普金斯彭博公共卫生学院健康咨询委员会担任主席。他拥有圣十字学院的金融会计学士学位以及哥伦比亚大学的金融工商管理学硕士学位。


Edward J. Ludwig,is the former Chairman of the Board of Becton, Dickinson and Company (BDX), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX's Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig was a member of the board of directors of POCARED Diagnostics Ltd, a privately held company focused on infectious disease diagnostics from 2013 to 2022. He formerly served as a director of Aetna, Inc., Xylem, Inc. and as Vice Chair of the board of trustees of the Hackensack University Medical Center Network.The College of the Holy Cross, B.A. in Economics and Accounting; Columbia University, M.B.A..
Edward J. Ludwig于2011年10月31日进入公司董事会。他于2012年7月在贝克顿公司、迪金森公司和BD公司担任董事长职务。他于1979年加入BD 公司,自2000年1月至2011年9月期间内他担任首席执行官、总裁、财务总监以及其他职务。再加入BD公司之前,他在永道会计师事务所(现在被称为普华永道律师事务所)担任高级审计师,在此期间内,他获得了注册会计师资格证。并且在基德公司担任财务与策略分析师。他在安泰保险公司董事会担任首席董事,并在财务委员会董事会担任主席。他也在波士顿科学公司董事会任职。他在哈肯萨克大学医学中心网络董事会担任副董事长,他是战略咨询委员会资金使用费部门的一员并在POCARED公司担任主管。他是更高职员领导中心董事会成员之一。他任职于哥伦比亚商学院监督委员会。他在美国先进医疗技术协会担任董事会主席,美国先进医疗技术协会是世界上最大的医疗技术协会。他在约翰霍普金斯彭博公共卫生学院健康咨询委员会担任主席。他拥有圣十字学院的金融会计学士学位以及哥伦比亚大学的金融工商管理学硕士学位。
Edward J. Ludwig,is the former Chairman of the Board of Becton, Dickinson and Company (BDX), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX's Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig was a member of the board of directors of POCARED Diagnostics Ltd, a privately held company focused on infectious disease diagnostics from 2013 to 2022. He formerly served as a director of Aetna, Inc., Xylem, Inc. and as Vice Chair of the board of trustees of the Hackensack University Medical Center Network.The College of the Holy Cross, B.A. in Economics and Accounting; Columbia University, M.B.A..
John E. Sununu

John E. Sununu,自2009年4月起担任波士顿科技公司的董事。从2003年至2009年,他曾担任新罕布什尔州的参议员。他是银行业、商业、金融业和外交关系委员会的成员;他被任命为联合国大会的国会代表。在当选为参议院议员前,从1996年至2002年,他曾担任三届来自新罕布什尔州第一区的众议院议员。他是预算委员会的副主席和拨款委员会的成员。在过去在国会的十二年,他起草并帮助通过几个重要的法例,包括互联网免税法案、幸存者福利法和新英格兰荒野保护法。在国会任职前,他曾担Teletrol系统公司的任首席财务官,这是一家建立控制系统的制造商。他同时还任职于时代华纳有线公司。他持有麻省理工学院的机械工程学士学位和哈佛商学院的工商管理硕士学位。


John E. Sununu,served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a member of the U.S. House of Representatives from New Hampshire's 1st District from 1996 to 2002, where he was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu currently serves as a Council Member of Lloyds of London, and formerly served as a director of Time Warner Cable Inc. and several private and charitable entities.Massachusetts Institute of Technology, B.S. and M.S. in Mechanical Engineering; Harvard University, M.B.A..
John E. Sununu,自2009年4月起担任波士顿科技公司的董事。从2003年至2009年,他曾担任新罕布什尔州的参议员。他是银行业、商业、金融业和外交关系委员会的成员;他被任命为联合国大会的国会代表。在当选为参议院议员前,从1996年至2002年,他曾担任三届来自新罕布什尔州第一区的众议院议员。他是预算委员会的副主席和拨款委员会的成员。在过去在国会的十二年,他起草并帮助通过几个重要的法例,包括互联网免税法案、幸存者福利法和新英格兰荒野保护法。在国会任职前,他曾担Teletrol系统公司的任首席财务官,这是一家建立控制系统的制造商。他同时还任职于时代华纳有线公司。他持有麻省理工学院的机械工程学士学位和哈佛商学院的工商管理硕士学位。
John E. Sununu,served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a member of the U.S. House of Representatives from New Hampshire's 1st District from 1996 to 2002, where he was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu currently serves as a Council Member of Lloyds of London, and formerly served as a director of Time Warner Cable Inc. and several private and charitable entities.Massachusetts Institute of Technology, B.S. and M.S. in Mechanical Engineering; Harvard University, M.B.A..
Charles J. Dockendorff

Charles J. Dockendorff,自2006年12月起成为Covidien的执行副总裁兼首席财务官。在此之前,从1995年10月到2006年11月他担任公司副总裁兼首席财务官。


Charles J. Dockendorff,was appointed to Hologic, Inc. Board in May 2017. He was formerly Executive Vice President and Chief Financial Officer of Covidien plc, a global medical device and supplies company. He was CFO at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller in 1994. He was appointed Chief Financial Officer of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation.Mr. Dockendorff holds a bachelor's degree in accounting from the University of Massachusetts at Amherst and a Master of Science in finance from Bentley College.
Charles J. Dockendorff,自2006年12月起成为Covidien的执行副总裁兼首席财务官。在此之前,从1995年10月到2006年11月他担任公司副总裁兼首席财务官。
Charles J. Dockendorff,was appointed to Hologic, Inc. Board in May 2017. He was formerly Executive Vice President and Chief Financial Officer of Covidien plc, a global medical device and supplies company. He was CFO at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller in 1994. He was appointed Chief Financial Officer of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation.Mr. Dockendorff holds a bachelor's degree in accounting from the University of Massachusetts at Amherst and a Master of Science in finance from Bentley College.
David S. Wichmann

David S. Wichmann,自1998年以来,担任联合健康集团的运营和技术总裁兼首席财务官,一家多元化的健康福祉公司。自2011年1月以来,他在联合健康集团担任多个行政职务,包括运营和技术部总裁,商业市场集团总裁、联合健康集团首席营运官,专业护理服务部总裁兼首席执行官、和公司发展部高级副总裁。1995年至1998年,担任安达信律师事务所的合伙人。自1992年至1994年,担任高级机械公司的财务总监。担任审计委员会、补偿和执行委员会的成员。


David S. Wichmann,is the former Chief Executive Officer of UnitedHealth Group, Incorporated, having served in that position from September 2017 through March 2021. Prior to this role, he served as President, UnitedHealth Group, beginning in November 2014, with oversight responsibility for all of UnitedHealthcare's domestic and international businesses, and for overall UnitedHealth Group performance, and as Chief Financial Officer of the UnitedHealth Group from 2011 until 2016. In addition, during his time at UnitedHealth Group, he held positions as President, UnitedHealthcare; President and Chief Executive Officer, Specialized Care Services (now OptumHealth); and Senior Vice President, Corporate Development. Prior to joining UnitedHealth Group, Mr. Wichmann was a partner at Arthur Andersen & Co. and Chief Financial Officer of Advanced Machine Company. He previously served on the boards of UnitedHealth Group, Incorporated and Tennant Company.Illinois State University, B.S. in Accounting.
David S. Wichmann,自1998年以来,担任联合健康集团的运营和技术总裁兼首席财务官,一家多元化的健康福祉公司。自2011年1月以来,他在联合健康集团担任多个行政职务,包括运营和技术部总裁,商业市场集团总裁、联合健康集团首席营运官,专业护理服务部总裁兼首席执行官、和公司发展部高级副总裁。1995年至1998年,担任安达信律师事务所的合伙人。自1992年至1994年,担任高级机械公司的财务总监。担任审计委员会、补偿和执行委员会的成员。
David S. Wichmann,is the former Chief Executive Officer of UnitedHealth Group, Incorporated, having served in that position from September 2017 through March 2021. Prior to this role, he served as President, UnitedHealth Group, beginning in November 2014, with oversight responsibility for all of UnitedHealthcare's domestic and international businesses, and for overall UnitedHealth Group performance, and as Chief Financial Officer of the UnitedHealth Group from 2011 until 2016. In addition, during his time at UnitedHealth Group, he held positions as President, UnitedHealthcare; President and Chief Executive Officer, Specialized Care Services (now OptumHealth); and Senior Vice President, Corporate Development. Prior to joining UnitedHealth Group, Mr. Wichmann was a partner at Arthur Andersen & Co. and Chief Financial Officer of Advanced Machine Company. He previously served on the boards of UnitedHealth Group, Incorporated and Tennant Company.Illinois State University, B.S. in Accounting.
David J. Roux

David J. Roux,自2014年1月起担任波士顿科技公司的董事。他是银湖投资集团的共同创办人兼高级总监,这是一家专注于技术投资的私人股本公司。他曾是利瑞科技公司的总裁兼CEO、甲骨文公司的执行副总裁和莲花发展公司的高级副总裁。 2008年12月至2012年12月,他曾担任亚美亚公司的董事局成员;2007年1月至2012年12月,担任亚美亚控股集团董事会成员;2006年3月至2011年3月,担任盛瑞纳软件公司董事会成员; 2010年5月至2012年1月,担任国际通信卫星有限公司董事会成员。他拥有哈佛商学院的工商管理硕士学位和剑桥大学国王学院的哲学硕士学位。他还是哈佛学院的研究生。


David J. Roux,is co-founder and co-managing partner of BayPine Capital, a private equity partnership established in October 2020. He served as a trustee and later Chairman of Jackson Laboratories, an independent biomedical research institute from 2011 to August 2022. He is the co-founder and was the Chairman, Co-Chief Executive Officer and Managing Partner of Silver Lake, a private equity firm focused on technology investing, from January 1999 to December 2017. Prior to that, Mr. Roux was Chairman and Chief Executive Officer of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development. He is also Chairman of Bristol Seafoods and was Vice Chairman of the National Audubon Society. He previously served as a director of Avaya Inc., Avaya Holdings Corp. and Intelsat S.A. Mr. Roux is co-founder of The Roux Institute, an educational partnership with Northeastern University.
David J. Roux,自2014年1月起担任波士顿科技公司的董事。他是银湖投资集团的共同创办人兼高级总监,这是一家专注于技术投资的私人股本公司。他曾是利瑞科技公司的总裁兼CEO、甲骨文公司的执行副总裁和莲花发展公司的高级副总裁。 2008年12月至2012年12月,他曾担任亚美亚公司的董事局成员;2007年1月至2012年12月,担任亚美亚控股集团董事会成员;2006年3月至2011年3月,担任盛瑞纳软件公司董事会成员; 2010年5月至2012年1月,担任国际通信卫星有限公司董事会成员。他拥有哈佛商学院的工商管理硕士学位和剑桥大学国王学院的哲学硕士学位。他还是哈佛学院的研究生。
David J. Roux,is co-founder and co-managing partner of BayPine Capital, a private equity partnership established in October 2020. He served as a trustee and later Chairman of Jackson Laboratories, an independent biomedical research institute from 2011 to August 2022. He is the co-founder and was the Chairman, Co-Chief Executive Officer and Managing Partner of Silver Lake, a private equity firm focused on technology investing, from January 1999 to December 2017. Prior to that, Mr. Roux was Chairman and Chief Executive Officer of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development. He is also Chairman of Bristol Seafoods and was Vice Chairman of the National Audubon Society. He previously served as a director of Avaya Inc., Avaya Holdings Corp. and Intelsat S.A. Mr. Roux is co-founder of The Roux Institute, an educational partnership with Northeastern University.

高管简历

中英对照 |  中文 |  英文
Michael F. Mahoney

Michael F. Mahoney,自2012年11月起担任公司总裁、首席执行官兼董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。


Michael F. Mahoney,has been the President of Boston Scientific Corporation ("Boston Scientific"; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. Mr. Mahoney has a bachelor's degree in Finance from the University of Iowa and an M.B.A. from Wake Forest University. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. (NYSE: BAX), a multinational health care company. He is currently a member of the Board of Directors of the Boys and Girls Club of Boston, a member of the American Heart Association CEO Roundtable, and is Chair of the Board of Governors of the Boston College Chief Executives Club.
Michael F. Mahoney,自2012年11月起担任公司总裁、首席执行官兼董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney,has been the President of Boston Scientific Corporation ("Boston Scientific"; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. Mr. Mahoney has a bachelor's degree in Finance from the University of Iowa and an M.B.A. from Wake Forest University. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. (NYSE: BAX), a multinational health care company. He is currently a member of the Board of Directors of the Boys and Girls Club of Boston, a member of the American Heart Association CEO Roundtable, and is Chair of the Board of Governors of the Boston College Chief Executives Club.
John B. Sorenson

John B. Sorenson是Boston Scientific Corporation全球运营执行副总裁,自2022年5月起担任该职位。在这个职位上,他负责监督全球供应链、质量和监管事务、全球企业卓越、信息技术、安全、企业研发、航空、全球设施、房地产和环境健康与安全。在担任现职之前,他曾于2021年9月至2022年5月担任全球供应链高级副总裁。在这个职位上,他负责Boston Scientific Corporation产品的全球制造和分销。他曾于2014年11月至2021年9月担任制造和供应链高级副总裁,并于2008年至2014年担任多站点运营副总裁。Sorenson先生曾在公司担任多个运营职位,支持心律管理、神经调节、介入心脏病学、外周介入和结构性心脏业务,并拥有20多年的医疗器械制造经验。他是Boston Scientific Corporation全球包容性理事会的成员,并担任Boston Scientific Corporation青年专业人员网络雇员资源小组的执行赞助人。在加入Boston Scientific Corporation之前,他是QRS Diagnostic的总裁兼首席运营官,并在Federal Cartridge担任制造管理职位。Sorenson在古斯塔夫斯·阿道夫学院获得经济学学士学位,在Minnesota大学获得工商管理硕士学位。


John B. Sorenson,is Boston Scientific Corporation Executive Vice President, Global Operations, a position he has held since May 2022. In this role, he is responsible for oversight of Global Supply Chain, Quality and Regulatory Affairs, Global Enterprise Excellence, Information Technology, Security, Corporate Research and Development, Aviation, Global Facilities, Real Estate and Environmental Health and Safety. Prior to his current role, he served as Senior Vice President, Global Supply Chain from September 2021 to May 2022. In this role he was responsible for the global manufacturing and distribution of Boston Scientific Corporation products. He previously served as Senior Vice President, Manufacturing and Supply Chain from November 2014 to September 2021, and as Multi-Site Vice President, Operations from 2008 to 2014. Mr. Sorenson has held a variety of operations positions at the Company, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses and has more than 20 years of medical device manufacturing experience. He is a member of Boston Scientific Corporation Global Council for Inclusion and serves as the executive sponsor for Boston Scientific Corporation Young Professionals Network employee resource group. Before joining the Company, he was president and chief operating officer of QRS Diagnostic and held manufacturing management positions at Federal Cartridge. Mr. Sorenson earned a B.A. in Economics from Gustavus Adolphus College and an M.B.A. from the University of Minnesota.
John B. Sorenson是Boston Scientific Corporation全球运营执行副总裁,自2022年5月起担任该职位。在这个职位上,他负责监督全球供应链、质量和监管事务、全球企业卓越、信息技术、安全、企业研发、航空、全球设施、房地产和环境健康与安全。在担任现职之前,他曾于2021年9月至2022年5月担任全球供应链高级副总裁。在这个职位上,他负责Boston Scientific Corporation产品的全球制造和分销。他曾于2014年11月至2021年9月担任制造和供应链高级副总裁,并于2008年至2014年担任多站点运营副总裁。Sorenson先生曾在公司担任多个运营职位,支持心律管理、神经调节、介入心脏病学、外周介入和结构性心脏业务,并拥有20多年的医疗器械制造经验。他是Boston Scientific Corporation全球包容性理事会的成员,并担任Boston Scientific Corporation青年专业人员网络雇员资源小组的执行赞助人。在加入Boston Scientific Corporation之前,他是QRS Diagnostic的总裁兼首席运营官,并在Federal Cartridge担任制造管理职位。Sorenson在古斯塔夫斯·阿道夫学院获得经济学学士学位,在Minnesota大学获得工商管理硕士学位。
John B. Sorenson,is Boston Scientific Corporation Executive Vice President, Global Operations, a position he has held since May 2022. In this role, he is responsible for oversight of Global Supply Chain, Quality and Regulatory Affairs, Global Enterprise Excellence, Information Technology, Security, Corporate Research and Development, Aviation, Global Facilities, Real Estate and Environmental Health and Safety. Prior to his current role, he served as Senior Vice President, Global Supply Chain from September 2021 to May 2022. In this role he was responsible for the global manufacturing and distribution of Boston Scientific Corporation products. He previously served as Senior Vice President, Manufacturing and Supply Chain from November 2014 to September 2021, and as Multi-Site Vice President, Operations from 2008 to 2014. Mr. Sorenson has held a variety of operations positions at the Company, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses and has more than 20 years of medical device manufacturing experience. He is a member of Boston Scientific Corporation Global Council for Inclusion and serves as the executive sponsor for Boston Scientific Corporation Young Professionals Network employee resource group. Before joining the Company, he was president and chief operating officer of QRS Diagnostic and held manufacturing management positions at Federal Cartridge. Mr. Sorenson earned a B.A. in Economics from Gustavus Adolphus College and an M.B.A. from the University of Minnesota.
Eric Thepaut

Eric Thepaut是Boston Scientific Corporation执行副总裁兼欧洲、中东和非洲总裁,自2020年2月起担任该职位。在担任现职之前,他曾于2017年12月至2020年1月担任欧洲、中东和非洲高级副总裁兼总裁,并于2015年1月至2017年12月担任欧洲高级副总裁兼总裁。2012年12月至2015年12月,他还担任欧洲介入心脏病学和结构心脏副总裁。他于1996年加入Boston Scientific Corporation欧洲公司,担任业务财务经理,并在市场营销和财务领域担任越来越重要的职务,包括欧洲财务副总裁、法国总经理和副总裁,以及法国集团的总经理和副总裁,Boston Scientific Corporation由法国、比荷卢和中东北非组成。Thepaut先生是Boston Scientific Corporation全球包容理事会的成员。在加入Boston Scientific Corporation公司之前,Thepaut先生曾在Nestle 担任财务运营和审计管理职务,在Apple, Inc.(当时的Apple Computer, Inc.)担任财务规划和分析管理职务。Thepaut先生在Paris Dauphine大学获得了工商管理硕士学位。


Eric Thepaut,is Boston Scientific Corporation Executive Vice President and President, Europe, Middle East and Africa, a position he has held since February 2020. Prior to his current role, he was Senior Vice President and President, Europe, Middle East and Africa from December 2017 to January 2020, and Senior Vice President and President, Europe from January 2015 to December 2017. He also served as Vice President, Interventional Cardiology & Structural Heart, Europe from December 2012 to December 2015. He joined Boston Scientific Europe in 1996 as a business finance manager and earned roles of increasing responsibility in marketing and finance including Vice President, Finance, Europe, General Manager and Vice President, France, and General Manager and Vice President of the France Group, comprised of France, Benelux and Middle East North Africa. Mr. Thepaut is a member of Boston Scientific Corporation Global Council for Inclusion. Before joining the Company, Mr. Thepaut held management positions in Treasury Operations and Auditing at Nestle and Financial Planning and Analysis at Apple, Inc. (then Apple Computer, Inc.). Mr. Thepaut earned his M.B.A. at Paris Dauphine University.
Eric Thepaut是Boston Scientific Corporation执行副总裁兼欧洲、中东和非洲总裁,自2020年2月起担任该职位。在担任现职之前,他曾于2017年12月至2020年1月担任欧洲、中东和非洲高级副总裁兼总裁,并于2015年1月至2017年12月担任欧洲高级副总裁兼总裁。2012年12月至2015年12月,他还担任欧洲介入心脏病学和结构心脏副总裁。他于1996年加入Boston Scientific Corporation欧洲公司,担任业务财务经理,并在市场营销和财务领域担任越来越重要的职务,包括欧洲财务副总裁、法国总经理和副总裁,以及法国集团的总经理和副总裁,Boston Scientific Corporation由法国、比荷卢和中东北非组成。Thepaut先生是Boston Scientific Corporation全球包容理事会的成员。在加入Boston Scientific Corporation公司之前,Thepaut先生曾在Nestle 担任财务运营和审计管理职务,在Apple, Inc.(当时的Apple Computer, Inc.)担任财务规划和分析管理职务。Thepaut先生在Paris Dauphine大学获得了工商管理硕士学位。
Eric Thepaut,is Boston Scientific Corporation Executive Vice President and President, Europe, Middle East and Africa, a position he has held since February 2020. Prior to his current role, he was Senior Vice President and President, Europe, Middle East and Africa from December 2017 to January 2020, and Senior Vice President and President, Europe from January 2015 to December 2017. He also served as Vice President, Interventional Cardiology & Structural Heart, Europe from December 2012 to December 2015. He joined Boston Scientific Europe in 1996 as a business finance manager and earned roles of increasing responsibility in marketing and finance including Vice President, Finance, Europe, General Manager and Vice President, France, and General Manager and Vice President of the France Group, comprised of France, Benelux and Middle East North Africa. Mr. Thepaut is a member of Boston Scientific Corporation Global Council for Inclusion. Before joining the Company, Mr. Thepaut held management positions in Treasury Operations and Auditing at Nestle and Financial Planning and Analysis at Apple, Inc. (then Apple Computer, Inc.). Mr. Thepaut earned his M.B.A. at Paris Dauphine University.
Arthur C. Butcher

Arthur C. Butcher是Boston Scientific Corporation执行副总裁兼MedSurg和亚太区集团总裁,自2022年5月起担任该职位。在这个职位上,他负责监督亚太地区,以及Boston Scientific Corporation泌尿外科内窥镜检查和神经调节业务。在担任现职之前,Butcher先生于2020年2月至2022年5月担任Boston Scientific Corporation执行副总裁兼亚太区总裁,负责Boston Scientific Corporation在亚太地区所有部门的全部产品组合的商业化。此前,Butcher曾担任Boston Scientific Corporation高级副总裁兼内窥镜总裁,2016年7月至2020年2月担任该职位。在这个职位上,他负责开发用于治疗胃肠道和肺部疾病的侵入性较小的设备并将其推向市场。2014年8月至2016年6月,他还担任日本内窥镜副总裁兼总经理。Butcher先生曾在内窥镜和泌尿外科部门担任过多个营销和战略规划管理职位,包括2011年4月至2014年8月的内窥镜部门全球营销副总裁,以及泌尿外科和女性健康部门新业务发展和战略规划副总裁。自1997年加入Boston Scientific Corporation公司以来,Butcher先生一直担任管理职务,责任越来越大,在各个部门都有丰富的经验。Butcher先生是Boston Scientific Corporation全球包容性理事会的成员,也是中国上市医疗器械公司Acotec Scientific董事会的提名成员。他拥有宾夕法尼亚大学国际关系学士学位和哥伦比亚大学工商管理硕士学位。


Arthur C. Butcher,is Boston Scientific Corporation Executive Vice President and Group President, MedSurg and Asia Pacific, a position he has held since May 2022. In this role, he is responsible for oversight of Asia Pacific, as well as Boston Scientific Corporation Urology Endoscopy and Neuromodulation businesses. Prior to his current role, Mr. Butcher served as Boston Scientific Corporation Executive Vice President and President, Asia Pacific from February 2020 to May 2022, and was responsible for commercialization of Boston Scientific Corporation full portfolio of products across all divisions in the Asia Pacific region. Previously, Mr. Butcher served as Boston Scientific Corporation Senior Vice President and President, Endoscopy, a position he held from July 2016 until February 2020. In this role, he was responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions. He also served as Vice President & General Manager, Japan Endoscopy from August 2014 to June 2016. Mr. Butcher has held a variety of marketing and strategic planning management positions within the Endoscopy and Urology businesses, including Vice President of Global Marketing, Endoscopy Division from April 2011 to August 2014, and Vice President of New Business Development and Strategic Planning, Urology & Women's Health. Since joining the Company in 1997, Mr. Butcher has held management roles with increasing responsibility and has deep experience across divisions. Mr. Butcher is a member of Boston Scientific Corporation Global Council for Inclusion and a nominee member of the board of directors of Acotec Scientific, a publicly traded Chinese medical device company. He holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.
Arthur C. Butcher是Boston Scientific Corporation执行副总裁兼MedSurg和亚太区集团总裁,自2022年5月起担任该职位。在这个职位上,他负责监督亚太地区,以及Boston Scientific Corporation泌尿外科内窥镜检查和神经调节业务。在担任现职之前,Butcher先生于2020年2月至2022年5月担任Boston Scientific Corporation执行副总裁兼亚太区总裁,负责Boston Scientific Corporation在亚太地区所有部门的全部产品组合的商业化。此前,Butcher曾担任Boston Scientific Corporation高级副总裁兼内窥镜总裁,2016年7月至2020年2月担任该职位。在这个职位上,他负责开发用于治疗胃肠道和肺部疾病的侵入性较小的设备并将其推向市场。2014年8月至2016年6月,他还担任日本内窥镜副总裁兼总经理。Butcher先生曾在内窥镜和泌尿外科部门担任过多个营销和战略规划管理职位,包括2011年4月至2014年8月的内窥镜部门全球营销副总裁,以及泌尿外科和女性健康部门新业务发展和战略规划副总裁。自1997年加入Boston Scientific Corporation公司以来,Butcher先生一直担任管理职务,责任越来越大,在各个部门都有丰富的经验。Butcher先生是Boston Scientific Corporation全球包容性理事会的成员,也是中国上市医疗器械公司Acotec Scientific董事会的提名成员。他拥有宾夕法尼亚大学国际关系学士学位和哥伦比亚大学工商管理硕士学位。
Arthur C. Butcher,is Boston Scientific Corporation Executive Vice President and Group President, MedSurg and Asia Pacific, a position he has held since May 2022. In this role, he is responsible for oversight of Asia Pacific, as well as Boston Scientific Corporation Urology Endoscopy and Neuromodulation businesses. Prior to his current role, Mr. Butcher served as Boston Scientific Corporation Executive Vice President and President, Asia Pacific from February 2020 to May 2022, and was responsible for commercialization of Boston Scientific Corporation full portfolio of products across all divisions in the Asia Pacific region. Previously, Mr. Butcher served as Boston Scientific Corporation Senior Vice President and President, Endoscopy, a position he held from July 2016 until February 2020. In this role, he was responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions. He also served as Vice President & General Manager, Japan Endoscopy from August 2014 to June 2016. Mr. Butcher has held a variety of marketing and strategic planning management positions within the Endoscopy and Urology businesses, including Vice President of Global Marketing, Endoscopy Division from April 2011 to August 2014, and Vice President of New Business Development and Strategic Planning, Urology & Women's Health. Since joining the Company in 1997, Mr. Butcher has held management roles with increasing responsibility and has deep experience across divisions. Mr. Butcher is a member of Boston Scientific Corporation Global Council for Inclusion and a nominee member of the board of directors of Acotec Scientific, a publicly traded Chinese medical device company. He holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.
Vance R. Brown

Vance R. Brown 是Boston Scientific Corporation的高级副总裁、总法律顾问和公司秘书,自 2021 年 6 月起担任该职位。在此职位上,他负责为Boston Scientific Corporation所有的业务、地区和职能部门提供全球法律领导,并监督公司的全球合规职能。在担任此职务之前,Brown 先生曾担任Boston Scientific Corporation的副总裁、首席公司法律顾问和助理秘书,他在 2010 年至 2021 年 6 月期间担任该职位。在该职位上,他负责领导和监督Boston Scientific Corporation的国际法律团队和各种公司法律职能,包括并购、风险投资、公司治理和证券。在此之前,布朗先生担任过各种法律和合规职务,对公司的责任越来越大。此外,布朗先生是Boston Scientific Corporation全球包容性委员会的成员 在加入波士顿科学之前,他是 Skadden、Arps、Slate、Meagher 和 Flom 的律师。他获得了学士学位。来自西安大略大学,他在哈佛法学院获得法学博士学位。


Vance R. Brown,is Boston Scientific Corporation Senior Vice President, General Counsel and Corporate Secretary, a position he has held since June 2021. In this role, he is responsible for providing global legal leadership across all of Boston Scientific Corporation businesses, regions and functions, and for overseeing the Company's global compliance function. Prior to this role, Mr. Brown served as Boston Scientific Corporation Vice President, Chief Corporate Counsel and Assistant Secretary, a position he held from 2010 to June 2021. In that role, he was responsible for leadership and oversight over Boston Scientific Corporation international legal teams and various corporate legal functions, including mergers and acquisitions, venture capital, corporate governance and securities. Prior to that, Mr. Brown held a variety of legal and compliance roles of increasing responsibility for the Company. Mr. Brown is a member of Boston Scientific Corporation Global Council for Inclusion. Before joining the Company, he was an attorney with Skadden, Arps, Slate, Meagher and Flom. He earned his B.A. from University of Western Ontario and his J.D. from Harvard Law School.
Vance R. Brown 是Boston Scientific Corporation的高级副总裁、总法律顾问和公司秘书,自 2021 年 6 月起担任该职位。在此职位上,他负责为Boston Scientific Corporation所有的业务、地区和职能部门提供全球法律领导,并监督公司的全球合规职能。在担任此职务之前,Brown 先生曾担任Boston Scientific Corporation的副总裁、首席公司法律顾问和助理秘书,他在 2010 年至 2021 年 6 月期间担任该职位。在该职位上,他负责领导和监督Boston Scientific Corporation的国际法律团队和各种公司法律职能,包括并购、风险投资、公司治理和证券。在此之前,布朗先生担任过各种法律和合规职务,对公司的责任越来越大。此外,布朗先生是Boston Scientific Corporation全球包容性委员会的成员 在加入波士顿科学之前,他是 Skadden、Arps、Slate、Meagher 和 Flom 的律师。他获得了学士学位。来自西安大略大学,他在哈佛法学院获得法学博士学位。
Vance R. Brown,is Boston Scientific Corporation Senior Vice President, General Counsel and Corporate Secretary, a position he has held since June 2021. In this role, he is responsible for providing global legal leadership across all of Boston Scientific Corporation businesses, regions and functions, and for overseeing the Company's global compliance function. Prior to this role, Mr. Brown served as Boston Scientific Corporation Vice President, Chief Corporate Counsel and Assistant Secretary, a position he held from 2010 to June 2021. In that role, he was responsible for leadership and oversight over Boston Scientific Corporation international legal teams and various corporate legal functions, including mergers and acquisitions, venture capital, corporate governance and securities. Prior to that, Mr. Brown held a variety of legal and compliance roles of increasing responsibility for the Company. Mr. Brown is a member of Boston Scientific Corporation Global Council for Inclusion. Before joining the Company, he was an attorney with Skadden, Arps, Slate, Meagher and Flom. He earned his B.A. from University of Western Ontario and his J.D. from Harvard Law School.
Jonathan Monson
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Emily Woodworth

Emily Woodworth目前担任财务副总裁兼公司泌尿外科业务财务总监,自2019年7月起担任该职位。在担任现职之前,Woodworth女士于2016年4月至2019年7月担任公司全球技术会计和外部报告总监,在此之前,她分别担任公司爱尔兰科克制造厂和神经调节业务的财务总监和财务总监。


Emily Woodworth,currently serves as Vice President of Finance and Controller of the Company's Urology business, a position she has held since July 2019. Prior to serving in her current role, Ms. Woodworth was Director of Global Technical Accounting and External Reporting at the Company from April 2016 through July 2019, and prior to that, served as Controller and Finance Director for the Company's Cork, Ireland manufacturing plant and Neuromodulation business, respectively.
Emily Woodworth目前担任财务副总裁兼公司泌尿外科业务财务总监,自2019年7月起担任该职位。在担任现职之前,Woodworth女士于2016年4月至2019年7月担任公司全球技术会计和外部报告总监,在此之前,她分别担任公司爱尔兰科克制造厂和神经调节业务的财务总监和财务总监。
Emily Woodworth,currently serves as Vice President of Finance and Controller of the Company's Urology business, a position she has held since July 2019. Prior to serving in her current role, Ms. Woodworth was Director of Global Technical Accounting and External Reporting at the Company from April 2016 through July 2019, and prior to that, served as Controller and Finance Director for the Company's Cork, Ireland manufacturing plant and Neuromodulation business, respectively.
Joseph M. Fitzgerald

Joseph M. Fitzgerald是Boston Scientific Corporation执行副总裁兼集团心脏病学总裁,自2022年5月起担任该职位。在这个职位上,他负责开发节律管理技术和创新解决方案,诊断和治疗冠状动脉疾病和结构性心脏疾病,并将其推向市场。他曾于2022年1月至2022年4月担任心脏病学执行副总裁兼总裁,于2020年7月至2022年1月担任介入心脏病学执行副总裁兼总裁,于2014年2月至2020年7月担任心律管理执行副总裁兼总裁,于2011年7月至2014年2月担任心律管理高级副总裁兼总裁。在此之前,他在2010年2月至2011年7月期间担任高级副总裁兼血管内血管总裁,并担任外周干预总裁兼总经理和电生理学总裁。Fitzgerald先生曾在Boston Scientific Corporation神经血管和外周介入业务部门担任过各种管理职务。其中包括许多地区和部门的销售管理任务,直到他担任神经血管业务全球营销副总裁和神经血管业务美国销售副总裁。Fitzgerald先生是Boston Scientific Corporation全球包容性理事会的成员,也是Boston Scientific Corporation EmpowHER员工资源小组的执行发起人。在1990年作为销售代表加入公司之前,Fitzgerald先生曾在Anheuser Busch公司工作,担任过各种销售、营销和培训任务。Fitzgerald先生拥有印第安纳大学商学学士学位和南伊利诺伊大学市场营销和金融专业的工商管理硕士学位。


Joseph M. Fitzgerald,is Boston Scientific Corporation Executive Vice President and Group President, Cardiology, a position he has held since May 2022. In this role, he is responsible for developing and bringing to market rhythm management technologies and innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. He previously served as Executive Vice President and President, Cardiology from January 2022 to April 2022, Executive Vice President and President, Interventional Cardiology, from July 2020 to January 2022, Executive Vice President and President, Rhythm Management from February 2014 until July 2020, and Senior Vice President and President, Cardiac Rhythm Management from July 2011 until February 2014. Prior to that, he was Senior Vice President and President, Endovascular from February 2010 until July 2011 and President and General Manager of Peripheral Interventions and President of Electrophysiology. Mr. Fitzgerald held a variety of management positions in Boston Scientific Corporation Neurovascular and Peripheral Interventions businesses. These included numerous regional and divisional sales management assignments up to and including his roles as Vice President, Global Marketing for the Neurovascular business and Vice President of U.S. sales for the Neurovascular business. Mr. Fitzgerald is a member of Boston Scientific Corporation Global Council for Inclusion and is executive sponsor of Boston Scientific Corporation EmpowHER employee resource group. Prior to joining the Company in 1990 as a sales representative, Mr. Fitzgerald was with Anheuser Busch, Inc., where he held a variety of sales, marketing and training assignments. Mr. Fitzgerald holds a B.S. in Business from Indiana University and an M.B.A. from Southern Illinois University with a concentration in Marketing and Finance.
Joseph M. Fitzgerald是Boston Scientific Corporation执行副总裁兼集团心脏病学总裁,自2022年5月起担任该职位。在这个职位上,他负责开发节律管理技术和创新解决方案,诊断和治疗冠状动脉疾病和结构性心脏疾病,并将其推向市场。他曾于2022年1月至2022年4月担任心脏病学执行副总裁兼总裁,于2020年7月至2022年1月担任介入心脏病学执行副总裁兼总裁,于2014年2月至2020年7月担任心律管理执行副总裁兼总裁,于2011年7月至2014年2月担任心律管理高级副总裁兼总裁。在此之前,他在2010年2月至2011年7月期间担任高级副总裁兼血管内血管总裁,并担任外周干预总裁兼总经理和电生理学总裁。Fitzgerald先生曾在Boston Scientific Corporation神经血管和外周介入业务部门担任过各种管理职务。其中包括许多地区和部门的销售管理任务,直到他担任神经血管业务全球营销副总裁和神经血管业务美国销售副总裁。Fitzgerald先生是Boston Scientific Corporation全球包容性理事会的成员,也是Boston Scientific Corporation EmpowHER员工资源小组的执行发起人。在1990年作为销售代表加入公司之前,Fitzgerald先生曾在Anheuser Busch公司工作,担任过各种销售、营销和培训任务。Fitzgerald先生拥有印第安纳大学商学学士学位和南伊利诺伊大学市场营销和金融专业的工商管理硕士学位。
Joseph M. Fitzgerald,is Boston Scientific Corporation Executive Vice President and Group President, Cardiology, a position he has held since May 2022. In this role, he is responsible for developing and bringing to market rhythm management technologies and innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. He previously served as Executive Vice President and President, Cardiology from January 2022 to April 2022, Executive Vice President and President, Interventional Cardiology, from July 2020 to January 2022, Executive Vice President and President, Rhythm Management from February 2014 until July 2020, and Senior Vice President and President, Cardiac Rhythm Management from July 2011 until February 2014. Prior to that, he was Senior Vice President and President, Endovascular from February 2010 until July 2011 and President and General Manager of Peripheral Interventions and President of Electrophysiology. Mr. Fitzgerald held a variety of management positions in Boston Scientific Corporation Neurovascular and Peripheral Interventions businesses. These included numerous regional and divisional sales management assignments up to and including his roles as Vice President, Global Marketing for the Neurovascular business and Vice President of U.S. sales for the Neurovascular business. Mr. Fitzgerald is a member of Boston Scientific Corporation Global Council for Inclusion and is executive sponsor of Boston Scientific Corporation EmpowHER employee resource group. Prior to joining the Company in 1990 as a sales representative, Mr. Fitzgerald was with Anheuser Busch, Inc., where he held a variety of sales, marketing and training assignments. Mr. Fitzgerald holds a B.S. in Business from Indiana University and an M.B.A. from Southern Illinois University with a concentration in Marketing and Finance.
Wendy Carruthers

Wendy Carruthers是Boston Scientific Corporation人力资源执行副总裁,自2022年2月起担任该职位。在此职位上,她负责监督公司在全球的人力资源活动,包括人力资源运营和服务、总奖励、人才管理、多样性和包容性以及社区参与。在担任现职之前,Carruthers女士从2012年12月至2022年2月担任人力资源高级副总裁,从2012年8月至2012年11月担任临时人力资源主管,并从2011年1月至2012年11月担任Boston Scientific Corporation全球人才管理副总裁。Carruthers女士自2004年以来一直在公司工作,曾担任多个职位,如Boston Scientific Corporation欧洲、中东和非洲地区人力资源副总裁;欧洲人力资源副总裁和欧洲人力资源总监。Carruthers女士是Boston Scientific Corporation全球包容理事会的共同主席。在加入Boston Scientific Corporation公司之前,Carruthers女士是欧洲有线和无线人力资源副总裁。Carruthers女士拥有Salford大学现代语言一级荣誉学士学位,并且是英国特许人事与发展学会的研究员。她是上市牙科制造和营销公司Envista Holdings Corporation、Boston Scientific基金会和大Boston食品银行Emeriti董事会的董事。


Wendy Carruthers,is Boston Scientific Corporation Executive Vice President, Human Resources, a position she has held since February 2022. In this role, she is responsible for overseeing the Company's human resources activities globally, including human resources operations and services, total rewards, talent management, diversity and inclusion and community engagement. Prior to her current role, Ms. Carruthers served as Senior Vice President, Human Resources from December 2012 until February 2022, the Head of Human Resources on an interim basis from August 2012 to November 2012, as well as Boston Scientific Corporation Vice President of Global Talent Management from January 2011 to November 2012. Ms. Carruthers has been with the Company since 2004 and has held various positions such as, Vice President of Human Resources for Boston Scientific Corporation Europe, Middle East and Africa region; Vice President of Human Resources for Europe and Director of Human Resources for Europe. Ms. Carruthers serves as a Co-Chair of Boston Scientific Corporation Global Council for Inclusion. Prior to joining the Company, Ms. Carruthers was Vice President of Human Resources, Europe for Cable & Wireless. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered Institute of Personnel and Development. She serves on the board of directors of Envista Holdings Corporation, a publicly traded dental manufacturing and marketing company, the Boston Scientific Foundation, and the Greater Boston Food Bank Emeriti Board.
Wendy Carruthers是Boston Scientific Corporation人力资源执行副总裁,自2022年2月起担任该职位。在此职位上,她负责监督公司在全球的人力资源活动,包括人力资源运营和服务、总奖励、人才管理、多样性和包容性以及社区参与。在担任现职之前,Carruthers女士从2012年12月至2022年2月担任人力资源高级副总裁,从2012年8月至2012年11月担任临时人力资源主管,并从2011年1月至2012年11月担任Boston Scientific Corporation全球人才管理副总裁。Carruthers女士自2004年以来一直在公司工作,曾担任多个职位,如Boston Scientific Corporation欧洲、中东和非洲地区人力资源副总裁;欧洲人力资源副总裁和欧洲人力资源总监。Carruthers女士是Boston Scientific Corporation全球包容理事会的共同主席。在加入Boston Scientific Corporation公司之前,Carruthers女士是欧洲有线和无线人力资源副总裁。Carruthers女士拥有Salford大学现代语言一级荣誉学士学位,并且是英国特许人事与发展学会的研究员。她是上市牙科制造和营销公司Envista Holdings Corporation、Boston Scientific基金会和大Boston食品银行Emeriti董事会的董事。
Wendy Carruthers,is Boston Scientific Corporation Executive Vice President, Human Resources, a position she has held since February 2022. In this role, she is responsible for overseeing the Company's human resources activities globally, including human resources operations and services, total rewards, talent management, diversity and inclusion and community engagement. Prior to her current role, Ms. Carruthers served as Senior Vice President, Human Resources from December 2012 until February 2022, the Head of Human Resources on an interim basis from August 2012 to November 2012, as well as Boston Scientific Corporation Vice President of Global Talent Management from January 2011 to November 2012. Ms. Carruthers has been with the Company since 2004 and has held various positions such as, Vice President of Human Resources for Boston Scientific Corporation Europe, Middle East and Africa region; Vice President of Human Resources for Europe and Director of Human Resources for Europe. Ms. Carruthers serves as a Co-Chair of Boston Scientific Corporation Global Council for Inclusion. Prior to joining the Company, Ms. Carruthers was Vice President of Human Resources, Europe for Cable & Wireless. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered Institute of Personnel and Development. She serves on the board of directors of Envista Holdings Corporation, a publicly traded dental manufacturing and marketing company, the Boston Scientific Foundation, and the Greater Boston Food Bank Emeriti Board.
Jeffrey B. Mirviss

Jeffrey B. Mirviss,自2020年2月以来,他一直担任Boston Scientific Corporation执行副总裁兼外围干预总裁。在此职位上,他负责开发并将治疗动脉和静脉系统阻塞和癌症患者的创新解决方案推向市场。此外,mirvis先生还负责Boston Scientific Corporation拉丁美洲、加拿大和政府事务团队。2013年1月至2020年1月,他担任Boston Scientific Corporation高级副总裁兼总裁,负责外围干预;2011年7月至2013年1月,担任外围干预总裁。自1997年加入公司以来,Mirviss先生还担任Boston Scientific Corporation集团全球营销、心脏病学、节律和血管副总裁,以及全球心脏病学营销副总裁。他是Boston Scientific Corporation Global Council for Inclusion的成员,也是Boston Scientific Corporation BRIDGE员工资源组(致力于招募、发展和留住黑人员工的组织)的执行发起人。在加入公司之前,他曾任职于规模不等的公司,从预营、风险投资支持的医疗设备初创公司到Dow 30公司。他持有University of Minnesota的学士学位和the University of St. Thomas的工商管理硕士学位。


Jeffrey B. Mirviss,is Boston Scientific Corporation Executive Vice President and President, Peripheral Interventions, a position he has held since February 2020. In this role, he is responsible for developing and bringing to market innovative solutions for treating patients with arterial and venous system blockages and cancer. In addition, Mr. Mirviss oversees Boston Scientific Corporation Latin America, Canada, and Government Affairs teams. Prior to his current role, he was Boston Scientific Corporation Senior Vice President and President, Peripheral Interventions, from January 2013 until January 2020, and President, Peripheral Interventions, from July 2011 to January 2013. Mr. Mirviss has more than 31 years of experience in medical device and pharmaceutical general management, marketing and sales. Since joining the Company in 1997, Mr. Mirviss has also served as Boston Scientific Corporation Vice President, Group Global Marketing, Cardiology, Rhythm and Vascular and Vice President, Global Cardiology Marketing. Mr. Mirviss is a member of Boston Scientific Corporation Global Council for Inclusion and is the executive sponsor of Boston Scientific Corporation BRIDGE employee resource group, an organization dedicated to recruitment, development, and retention of Black employees. Prior to joining the Company, Mr. Mirviss worked for companies ranging in size from a pre‐revenue, venture‐backed, medical device startup to Dow 30 companies. He holds a Bachelor's degree from the University of Minnesota and an M.B.A. from the University of St. Thomas.
Jeffrey B. Mirviss,自2020年2月以来,他一直担任Boston Scientific Corporation执行副总裁兼外围干预总裁。在此职位上,他负责开发并将治疗动脉和静脉系统阻塞和癌症患者的创新解决方案推向市场。此外,mirvis先生还负责Boston Scientific Corporation拉丁美洲、加拿大和政府事务团队。2013年1月至2020年1月,他担任Boston Scientific Corporation高级副总裁兼总裁,负责外围干预;2011年7月至2013年1月,担任外围干预总裁。自1997年加入公司以来,Mirviss先生还担任Boston Scientific Corporation集团全球营销、心脏病学、节律和血管副总裁,以及全球心脏病学营销副总裁。他是Boston Scientific Corporation Global Council for Inclusion的成员,也是Boston Scientific Corporation BRIDGE员工资源组(致力于招募、发展和留住黑人员工的组织)的执行发起人。在加入公司之前,他曾任职于规模不等的公司,从预营、风险投资支持的医疗设备初创公司到Dow 30公司。他持有University of Minnesota的学士学位和the University of St. Thomas的工商管理硕士学位。
Jeffrey B. Mirviss,is Boston Scientific Corporation Executive Vice President and President, Peripheral Interventions, a position he has held since February 2020. In this role, he is responsible for developing and bringing to market innovative solutions for treating patients with arterial and venous system blockages and cancer. In addition, Mr. Mirviss oversees Boston Scientific Corporation Latin America, Canada, and Government Affairs teams. Prior to his current role, he was Boston Scientific Corporation Senior Vice President and President, Peripheral Interventions, from January 2013 until January 2020, and President, Peripheral Interventions, from July 2011 to January 2013. Mr. Mirviss has more than 31 years of experience in medical device and pharmaceutical general management, marketing and sales. Since joining the Company in 1997, Mr. Mirviss has also served as Boston Scientific Corporation Vice President, Group Global Marketing, Cardiology, Rhythm and Vascular and Vice President, Global Cardiology Marketing. Mr. Mirviss is a member of Boston Scientific Corporation Global Council for Inclusion and is the executive sponsor of Boston Scientific Corporation BRIDGE employee resource group, an organization dedicated to recruitment, development, and retention of Black employees. Prior to joining the Company, Mr. Mirviss worked for companies ranging in size from a pre‐revenue, venture‐backed, medical device startup to Dow 30 companies. He holds a Bachelor's degree from the University of Minnesota and an M.B.A. from the University of St. Thomas.
Daniel J. Brennan

Daniel J. Brennan,现任本公司执行副总裁兼首席财务总监,并从2014年1月起担任该职位。任职期间,他负责公司的几个运行功能,其中包括全球财务控制、企业财务、司库、法人税、法人分析与控制以及企业业务发展。在此之前,他是公司的高级副总裁兼财务总监,并从自2010年1月起担任该职位。自1996年12月加入波士顿科技公司以来,他在公司里担任着愈发重要的角色,责任也随之增加。2009年,他担任副总裁及助理财务总监; 2001年至2008年,他担任财务副总裁;2008年,负责全球金融和战略规划部的信息技术;2006年至2007年,负责投资者关系;2005年至2006年,负责国际金融;2001年至2005年,负责心血管部门。 1999年,在担任Meditech血管科的主管后,他担任非血管科的总监。


Daniel J. Brennan,is Boston Scientific Corporation Executive Vice President and Chief Financial Officer, a position he has held since January 2014. In this role, he is responsible for several Company functions, including Global Controllership, Global Internal Audit, Corporate Finance, Treasury, Corporate Tax, Investor Relations, and Corporate Business Development. Prior to that, he was the Company's Senior Vice President and Corporate Controller, a role he served in from January 2010 to January 2014. Since joining the Company in December 1996, Mr. Brennan has held roles with increasing responsibilities, including Vice President and Assistant Corporate Controller, Vice President of Finance for Worldwide Financial and Strategic Planning, Investor Relations, International Finance and Cardiovascular, Group Controller of the Non-Vascular Business and Controller of the Meditech Vascular business. Mr. Brennan is the Co-Chair of Boston Scientific Corporation Global Council for Inclusion. He holds a B.S. degree in Finance and Investments and an M.B.A. from Babson College. Mr. Brennan is also a certified public accountant. He is currently a member of the board of directors of Waters Corporation, a publicly-traded analytical laboratory instrument and software company, and a former board member of Nuance Communications and Overseers of Babson College.
Daniel J. Brennan,现任本公司执行副总裁兼首席财务总监,并从2014年1月起担任该职位。任职期间,他负责公司的几个运行功能,其中包括全球财务控制、企业财务、司库、法人税、法人分析与控制以及企业业务发展。在此之前,他是公司的高级副总裁兼财务总监,并从自2010年1月起担任该职位。自1996年12月加入波士顿科技公司以来,他在公司里担任着愈发重要的角色,责任也随之增加。2009年,他担任副总裁及助理财务总监; 2001年至2008年,他担任财务副总裁;2008年,负责全球金融和战略规划部的信息技术;2006年至2007年,负责投资者关系;2005年至2006年,负责国际金融;2001年至2005年,负责心血管部门。 1999年,在担任Meditech血管科的主管后,他担任非血管科的总监。
Daniel J. Brennan,is Boston Scientific Corporation Executive Vice President and Chief Financial Officer, a position he has held since January 2014. In this role, he is responsible for several Company functions, including Global Controllership, Global Internal Audit, Corporate Finance, Treasury, Corporate Tax, Investor Relations, and Corporate Business Development. Prior to that, he was the Company's Senior Vice President and Corporate Controller, a role he served in from January 2010 to January 2014. Since joining the Company in December 1996, Mr. Brennan has held roles with increasing responsibilities, including Vice President and Assistant Corporate Controller, Vice President of Finance for Worldwide Financial and Strategic Planning, Investor Relations, International Finance and Cardiovascular, Group Controller of the Non-Vascular Business and Controller of the Meditech Vascular business. Mr. Brennan is the Co-Chair of Boston Scientific Corporation Global Council for Inclusion. He holds a B.S. degree in Finance and Investments and an M.B.A. from Babson College. Mr. Brennan is also a certified public accountant. He is currently a member of the board of directors of Waters Corporation, a publicly-traded analytical laboratory instrument and software company, and a former board member of Nuance Communications and Overseers of Babson College.